Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

Completed · Phase 1

Conditions studied: Kidney; Complications, Allograft

In brief

This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell injury in the kidney. The investigators hypothesize that complement inhibition with eculizumab will reduce allograft injury, resulting from less complement-mediated injury of endothelial cells and less endothelial cell activation.

Key facts

Study ID

NCT01327573

Run by

Sanjay Kulkarni

People needed

16

Starts

2011-03-01

Expected to finish

2015-02-01

Last updated by the study team

2019-08-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney transplant recipients greater than 6 months from the date of transplant
• Must be on standard immunosuppression: tacrolimus, mycophenolate mofetil, prednisone and have stable tacrolimus trough levels over past 3 months
• Deteriorating renal function, as defined by 20% reduction in GFR (MDRD calculation)
• Presence of DSA, as defined as MFI > 1100
• Renal biopsy demonstrating no diffuse, irreversible end-stage organ injury (i.e. stage IV Fibrosis)
• Renal biopsy demonstrating C4d deposition (stratum 1) or no C4d deposition (stratum 2)

You may not qualify if…

• History of CMV, BK, HSV or other viral infections
• History of chronic, recurrent bacterial infections
• Evidence of tubulitis on renal biopsy or other morphological features of acute cellular rejection or acute humoral rejection
• Renal biopsy demonstrating diffuse, irreversible end-stage organ injury
• Absolute GFR < 25 (MDRD calculation)
• Inability to provide informed consent
• History of poor vascular access
• Refusal to use double barrier contraception during study participation
• Patients actively enrolled in other clinical trials

Where it is running

• Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.